Table 1.
Characteristics of kidney transplant recipients strictly negative after 3 mRNA vaccines having received a fourth mRNA vaccine
| Characteristic | Negative (n = 28) |
Positive (n = 21) |
P value | ||||
|---|---|---|---|---|---|---|---|
| NA | No. | % | NA | No. | % | ||
| Male recipient | 0 | 15 | 53.6 | 0 | 8 | 38.1 | 0.38 |
| Transplant rank ≥2 | 0 | 4 | 14.3 | 0 | 2 | 9.5 | 0.68 |
| Calcineurin inhibitor treatment | 0 | 20 | 71.4 | 0 | 18 | 85.7 | 0.31 |
| mTOR inhibitor treatment | 0 | 0 | 0 | 0 | 1 | 4.7 | 0.43 |
| Antimetabolite treatment | 0 | 23 | 82.1 | 0 | 18 | 85.7 | 1 |
| Steroid treatment | 0 | 18 | 64.2 | 0 | 10 | 47.6 | 0.26 |
| Belatacept treatment | 0 | 0 | 0 | 0 | 1 | 4.7 | 0.43 |
| BNT162b (Pfizer) mRNA vaccine | 0 | 19 | 67.8 | 0 | 18 | 85.7 | 0.19 |
| Lymphocytes <1500/mm3 | 0 | 21 | 75.0 | 0 | 13 | 61.9 | 0.36 |
| CMV seropositive status | 0 | 17 | 60.7 | 1 | 8 | 40.0 | 0.15 |
| Presence of donor-specific antibody | 0 | 5 | 17.8 | 0 | 3 | 14.3 | 0.77 |
| History of biopsy-proven acute rejection |
0 |
6 |
21.4 |
0 |
1 |
4.8 |
0.21 |
|
NA |
Mean |
SD |
NA |
Mean |
SD |
P value |
|
| Age, yr | 0 | 63.4 | 11.1 | 0 | 62.4 | 12.8 | 0.87 |
| Time from transplantation, yr | 0 | 8.0 | 7.2 | 0 | 7.1 | 6.5 | 0.76 |
| Time between third and fourth vaccine, d | 0 | 82.6 | 25.7 | 0 | 93.4 | 31.7 | 0.30 |
| Anti-spike IgG titer, BAU/ml | 0 | 0.3 | 1.0 | 0 | 81.4 | 93.7 | < 0.001 |
| Allograft function by MDRD, ml/min | 0 | 43.2 | 18.8 | 0 | 40.1 | 13.5 | 0.73 |
BAU, binding antibody unit; CMV, cytomegalovirus; MDRD, Modification of Diet in Renal Disease; NA, not available.